Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a new, more efficient workflow process for the cobas HPV Test, allowing sample processing from the primary sample ...

Roche announced that the World Health Organization (WHO) has awarded the cobas HPV test prequalification designations for use on the cobas 5800 system and for self-collected samples on the cobas 5800, ...

Roche’s human papillomavirus solution is reportedly one of the first of its kind to be available in the United States. Roche announced that the FDA has approved its human papillomavirus(HPV) ...

More than half of all U.S. cervical cancer patients are underscreened 1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate ...

The HPV self-collection solution allows an individual to collect their own vaginal sample for HPV screening while at a health care facility. The Food and Drug Administration (FDA) has approved Roche’s ...

The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, ...

Basel, 15 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of its human papillomavirus (HPV) self-collection solution, one of the first available in the United States.

Introduction Self-sampling for cervical cancer screening is a promising strategy to improve coverage and reduce strain on ...

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...